Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2023 · 10-Q
Revenue—
Net Income-$1.99M-$1.99MN/M vs Q2 2022 EPS Diluted-$1.49-$1.49N/M vs Q2 2022 Operating Income-$3,621,000N/M Operating Cash Flowderived-$1,935,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 7, 2023 · 38 d after period end